Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma

FRIDAY, Sept. 4, 2020 -- For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news